For the Inventor, By the Inventor

Enter assignee name

Culver City, CA, United States of America

Nantbio, Inc.

USPTO Granted Patents = 57

EPO Patents = 7

Forward Citations = 43

Loading Chart...

Loading Chart...

62 inventors (with patents filed for the assignee):

Kayvan R Niazi (41 out of 99 patents)

Patrick Soon-Shiong (17 out of 475 patents)

Clifford Anders Olson (15 out of 17 patents)

4. Shahrooz Rabizadeh (11 out of 86 patents)

5. Shiho Tanaka (9 out of 12 patents)

6. Chunlin Tao (8 out of 32 patents)

7. Philip T Liu (7 out of 10 patents)

8. Qinwei Wang (7 out of 14 patents)

9. Wael Tadros (7 out of 7 patents)

10. Nicholas James Witchey (7 out of 160 patents)

11. Stephen Charles Benz (6 out of 57 patents)

12. Peter Sieling (6 out of 8 patents)

13. Raymond Wong (6 out of 9 patents)

14. Paul Weingarten (6 out of 10 patents)

15. Heather McFarlane (5 out of 5 patents)

Core Competencies:

Live Cell Imaging

Immune Response Validation

Mesenchymal Stem Cell Exosomes

Chimeric T Cell Receptors

Cellular Adjuvants

mRNA Display Antibody Library

Anti-TIM3 Monoclonal Antibodies

Targeted IL-12 Treatments

Tumor Characterization

Reprogrammed T Cell-like NK Cells

Viral Infection Treatments

Trk Inhibition

57 patents: Sort by Forward Citations

1. 12662681 - Multi-pulse transfection methods and cells (2026-06-23),

2. 12638456 - Cellular reporting for therapy production (2026-05-26),

3. 12595307 - Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors (2026-04-07),

4. 12545928 - Machine Methods To Determine Neoepitope Payload Toxicity (2026-02-10),

5. 12502404 - Conditional modulation of therapy using recombinant cells (2025-12-23),

6. 12416635 - Live cell imaging systems and methods to validate triggering of immune response (2025-09-16),

7. 12412639 - Method of characterizing a tumor based on an immune gene expression signature in regulatory T cell (Treg)-enriched tumor samples (2025-09-09),

8. 12397019 - Mesenchymal stem cell derived exosomes and methods (2025-08-26),

9. 12385903 - RP182 compositions and methods (2025-08-12),

10. 12350323 - Cellular adjuvants for viral infection (2025-07-08),

11. 12350316 - IL7-IL 15 TxM compositions and methods (2025-07-08),

12. 12329809 - Cellular adjuvants for viral infection (2025-06-17),

13. 12308095 - Prediction of computational pathway circuits (2025-05-20),

14. 12280092 - Reprogrammed T cell-like NK cells (2025-04-21),

15. 12263189 - Mesenchymal stem cell derived exosomes and methods (2025-04-01),

NantBio, Inc. is a biotechnology company focused on developing innovative and targeted therapeutics to address unmet medical needs. With a strong emphasis on cancer research, NantBio aims to revolutionize the treatment and diagnosis of various diseases. Through cutting-edge technology and strategic collaborations, the company is dedicated to improving patient outcomes and transforming the field of biomedicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

57 Patents

#8 in Culver City, CA

#1,463 in California

#6,237 in US

#12,538 in the World

Culver City, CA, United States of America

Nantbio, Inc.

Forward Citations = 43

62 inventors:

Kayvan R Niazi (41 out of 99 patents)

Patrick Soon-Shiong (17 out of 475 patents)

Clifford Anders Olson (15 out of 17 patents)

4. Shahrooz Rabizadeh (11 out of 86 patents)

5. Shiho Tanaka (9 out of 12 patents)

Please report any incorrect information to [email protected]

Loading…